Navigating AHA Scientific Statements: Advancing Evidence-Based Cardiovascular Care

Professor Bradley S. Marino shares his insights on the advancing evidence-based cardiovascular care at AHA Scientific Sessions 2025.

Aldosterone and Mineralocorticoid Receptors: New Paradigms and Novel Therapies

Professor John M. Flack shares his insights on the new paradigms and novel therapies in aldosterone and mineralocorticoid receptors at AHA Scientific Sessions 2025.

TUXEDO-2: Ticagrelor vs. Prasugrel in Patients With Diabetes and Multivessel Disease After PCI

Professor Sripal Bangalore discusses the findings from the TUXEDO-2 trial presented at at AHA Scientific Sessions 2025.

DASH-Patterned Groceries Reduce Blood Pressure

Professor Stephen P. Juraschek discusses the results from the GoFresh randomized clinical trial presented at at AHA Scientific Sessions 2025.

Blood Pressure and Symptomatic Hypotension with Dapagliflozin vs. Placebo in Patients Hospitalized with Heart Failure

Professor Siddharth M. Patel shares his insights on the results from the DAPA ACT HF-TIMI 68 trial at AHA Scientific Sessions 2025.

Effectiveness of High-Dose vs. Standard-Dose Inactivated Influenza Vaccine in Individuals with and without Atherosclerotic Cardiovascular Disease: A Pooled FLUNITY-HD Trial Analysis

Professor Manan Pareek shares his insights on the results from the FLUNITY-HD trial analysis at AHA Scientific Sessions 2025.

Remote BP Monitoring and Drug Titration – Does it work? How do we do it?

Professor Beverly B. Green shares her insights on remote BP monitoring and drug titrationat after the AHA Scientific Sessions 2025.

Highlights of AHA / ACC Blood Pressure Management Guideline

Professor Daniel Jones shares his insights on the AHA / ACC  Blood Pressure Management Guideline at AHA Scientific Sessions 2025.

Metformin as an Adjunctive Therapy to Catheter Ablation of Atrial Fibrillation

Professor Amrish Deshmukh shares his insights on metformin as an adjunctive therapy to catheter ablation of atrial fibrillation at AHA Scientific Sessions 2025.

Resistance Exercise Therapy After COVID-19 Infection: a Randomized, Controlled Trial

Professor Stuart Gray shares his insights on the resistance exercise therapy after COVID-19 infection at AHA Scientific Sessions 2025.

Impact of Cardiovascular-Focused Messaging to Improve Influenza Vaccination on Cardiovascular-Kidney-Metabolic Care Patterns and Clinical Outcomes: Insights from the KP VACCINATE Megatrial

Professor Ankeet Bhatt shares his insights from the KP VACCINATE Megatrial presented at at AHA Scientific Sessions 2025.

Once-weekly Tirzepatide versus Dulaglutide for Heart Failure Outcomes in Patients with Type 2 Diabetes, ASCVD, and History of Heart Failure

Professor Stephen Nicholls shares his insights on the pre-specified analysis of the SURPASS-CVOT Randomized Clinical Trial at AHA Scientific Sessions 2025.

First-in-human trial of CRISPR gene-editing therapy safely lowered cholesterol, triglycerides

Professor Stephen Nicholls shares his insights on the first-in-human trial of CRISPR gene-editing therapy at AHA Scientific Sessions 2025.

A Randomized Clinical Trial Evaluating Vitamin D Normalization on Major Adverse Cardiovascular-Related Events Among Acute Coronary Syndrome Patients: The TARGET-D Trial

Professor Heidi T. May explains heart attack risk halved in adults with heart disease taking tailored vitamin D doses at AHA Scientific Sessions 2025.

The New 2025 Guideline for Acute Coronary Syndromes: The European perspective

Professor Tiziana Claudia Aranzulla shares her insights on the Guideline for Acute Coronary Syndromes from the European perspective at AHA Scientific Sessions 2025.

The Clinicians view on the 2025 Guideline for Acute Coronary Syndromes

Professor Matthew Tomey discusses the clinicians view on the 2025 Guideline for Acute Coronary Syndromes at AHA Scientific Sessions 2025.